基于尿液外泌体 mRNA 的前列腺癌有效诊断

核心信息

• 论文英文标题: Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes
• 期刊: FRONT MED-LAUSANNE
• 发表年份: 2022
• DOI: 10.3389/fmed.2022.736110
• PMID/PMCID: 35402423; PMC8983915

研究概览

Novel non-invasive biomarkers are urgently required to improve the diagnostic sensitivity and specificity of prostate cancer (PCa). These findings suggested that mRNAs from urinary exosomes have the potential in serving as novel and non-invasive indicators for PCa diagnosis and prediction.

核心发现

The expression of urinary exosomal ERG, PCA3, PSMA, CK19, and EpCAM were significantly increased in patients with PCa compared with healthy males.

Kaplan-Meier curves demonstrated that PCA3, ARV7, and EpCAM were associated in androgen-deprivation therapy (ADT) failure time which is defined as from the initiation of ADT in hormone-sensitive stage to the development of castration-resistant prostate cancer.

研究设计

Exosomes were obtained using size-exclusion chromatography (SEC), out of which RNAs were extracted, then analyzed by quantitative reverse transcription-polymerase chain reaction according to manufacturer's protocol.

Echo Biotech 角色

qPCR

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: EV Isolation & Purification, qPCR Validation, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Effective Diagnosis of Prostate Cancer Based on mRNAs From Urinary Exosomes Frontiers in Medicine. 2022. DOI: 10.3389/fmed.2022.736110. PMID/PMCID: 35402423; PMC8983915.